Opinion|Videos|February 24, 2025
Patient and Caregiver Advice for Navigating Atopic Dermatitis
Panelists discuss offering guidance to parents and caregivers experiencing atopic dermatitis for the first time, emphasizing the importance of education on managing flare-ups, proper skin care routines, and setting realistic treatment expectations while also seeking support from health care professionals to navigate the challenges of the condition.
Advertisement
Episodes in this series
Video content above is prompted by the following:
9. What advice do you have for parents and caregivers who may be experiencing atopic dermatitis for the first time?
Advertisement
Related to this article
April Armstrong, MD, MPH, discusses 1-year RELIEVE-AD-PEDs data on rapid, sustained dupilumab disease control in adolescents with atopic dermatitis.
In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.
An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.
In this session, Cheri Frey, MD, shared a framework for evaluating skincare products, from ingredient plausibility to clinically meaningful results.
Andrea Murina, MD, reviewed strategies for optimizing HS biologics, combining therapies, and reconsidering the role of surgery.
HCPLive previews Fall Clinical 2026 in Las Vegas, October 8-11, with key sessions on atopic dermatitis, psoriasis, and vitiligo, plus expert interviews.
With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.
The guideline chair answers key questions on new ferritin cutoffs, symptoms without anemia, inflammation, and lab reporting.
Advertisement
Advertisement
Trending on HCPLive
1
New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity
2
Remibrutinib Receives FDA Approval for Symptomatic Dermographism
3
Why "Normal" Ferritin Can Miss Iron Deficiency, With Jacquelyn Powers, MD, MS
4
ZUPREME-2: Petrelintide Outperforms Placebo for Weight Loss in T2D and Obesity
5